Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025 year-end cash and cash equivalents of $226.

Dad with ALS died after believing stem cell center's claims it could treat him, leading to fatal procedure causing bleeding, brain herniation: Lawsuit

A Washington state jury awarded $24 million to the family of a man who died due to stem cell treatment negligence after ...

Rice-led research to develop first regenerative therapy for lymphedema receives up to $18.2M federal award

A team of researchers led by Rice University bioengineer Omid Veiseh has been awarded $18.2 million in funding from the Advanced Research Projects Agency for Health (ARPA-H) to develop a ...